Takaisin Tulosta

Intra-articular corticosteroid for treatment of osteoarthritis of the knee

Evidence summaries
22.8.2016 • Completely updated
Editors

Level of evidence: C

Intra-articular corticosteroids may improve pain and function in the treatment of knee osteoarthritis in the short term (up to 6 weeks). Longer term benefits have not been confirmed.

The quality of evidence is downgraded by study limitations (unclear allocation concealment and lack of blinding) and by inconsistency (unexplained variability in results).

Summary

A Cochrane review «Intra‐articular corticosteroid for knee osteoarthritis»1 «Jüni P, Hari R, Rutjes AW et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev 2015;(10):CD005328. . »1 included 27 studies, with a total of 1 767 subjects, comparing intra-articular (IA) corticosteroid against sham or no intervention. IA corticosteroids were more effective in pain reduction than control (SMD -0.40, 95% CI -0.58 to -0.22; statistical heterogeneity I2=68%; 26 studies, n=1 749), which corresponds to a difference in pain scores of 1.0 cm on a 10-cm visual analogue scale between corticosteroids and sham injection and translates into a number needed to treat for an additional beneficial outcome (NNTB) of 8 (95% CI 6 to 13). When stratifying results according to length of follow-up, improvements were observed at 1–2 weeks and 4–6 weeks, but there was no statistically significant differences at 3 and 6 months.

IA corticosteroids appeared to be more effective in function improvement than control (SMD -0.33, 95% CI -0.56 to -0.09; statistical heterogeneity I2=69%; 15 studies, n=1  014), which corresponds to a difference in functions scores of -0.7 units on standardised Western Ontario and McMaster Universities Arthritis Index (WOMAC) disability scale ranging from 0 to 10 and translates into a NNTB of 10 (95% CI 7 to 33). When stratifying results according to length of follow-up, benefits were observed at 1–2 weeks and 4–6 weeks, but there were no statistically significant differences at 3 or 6 months. There was no statistically significant difference in adverse events (RR 0.89, 95% CI 0.64 to 1.23; 2 studies, n=84) or serious adverse events (RR 0.63, 95% CI 0.15 to 2.67; 5 studies, n=331) between corticosteroids and control . There was no difference on quality of life between corticosteroids and control (SMD -0.01, 95% CI -0.30 to 0.28; 2 studies, n=184). There was also no evidence of an effect of corticosteroids on joint space narrowing compared to control interventions (SMD -0.02, 95% CI -0.49 to 0.46; 1 study, n=68).

References

  1. Jüni P, Hari R, Rutjes AW et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev 2015;(10):CD005328. «PMID: 26490760»PubMed.